We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock

Delisted

BIOR was delisted on the 10th of December, 2024.

24 hedge funds and large institutions have $25.9M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,356% more call options, than puts

Call options by funds: $2.34M | Put options by funds: $161K

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

96% more capital invested

Capital invested by funds: $13.2M → $25.9M (+$12.7M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

20% less funds holding

Funds holding: 3024 (-6)

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

Holders
24
Holders Change
-6
Holders Change %
-20%
% of All Funds
0.38%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
3
Increased
10
Reduced
5
Closed
9
Calls
$2.34M
Puts
$161K
Net Calls
+$2.18M
Net Calls Change
-$2.02M
Name Holding Trade Value Shares
Change
Change in
Stake
AFM
26
Anson Funds Management
Texas
-$2.38M -61,713 Closed
GCP
27
GSA Capital Partners
United Kingdom
-$148K -3,842 Closed
Creative Planning
28
Creative Planning
Kansas
-$84.7K -2,200 Closed
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
-$54.7K -1,706 Closed
Simplex Trading
30
Simplex Trading
Illinois
-$18.7K -583 Closed
UBS Group
31
UBS Group
Switzerland
-$7.11K -185 Closed
Bank of America
32
Bank of America
North Carolina
-$4.77K -124 Closed
AF
33
Advisornet Financial
Minnesota
-$593 -15 Closed
Fidelity Investments
34
Fidelity Investments
Massachusetts
-$100 -3 Closed

BIOR Hedge Fund Activity: Q3 2023 in Review

24 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2023, worth a combined $25.9M — up 96% from $13.2M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BIOR and 3 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 10 added.

The largest buyer was Athyrium Capital Management, adding an estimated $29.6M. The largest seller was Anson Funds Management, exiting entirely with an estimated $2.38M sold.

  • 24 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2023, down from 30 in Q2 2023.
  • Funds reported $25.9M of Biora Therapeutics, Inc. Common Stock stock for Q3 2023, up 96% quarter-over-quarter.
  • 3 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2023 and 9 closed out, a net change of -6 holders.
  • The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2023 was Athyrium Capital Management, an estimated $29.6M added.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2023 was Anson Funds Management, an estimated $2.38M sold.

Based on aggregated 13F filings for Q3 2023.